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Introduction In recent years, there has been growing 
interest in alternatives to appendicectomy. In particular, 
non-operative treatment of appendicitis, with antibiotics 
alone, has been proposed as a potential treatment. A 
small number of randomised controlled trials (RCTs) in 
adults and, more recently, children suggest that antibiotic 
treatment may be a valid alternative to appendicectomy. 
However, there is currently insufficient data to justify 
its widespread use. Prior to performing further efficacy 
studies of the treatment of appendicitis in children, it is 
imperative to identify the most relevant outcome measures 
for inclusion in the design of comparative studies. This 
is of particular importance when evaluating a novel 
treatment approach since the outcomes of importance 
may differ from those commonly reported with traditional 
therapies. A review of the relevant literature and electronic 
resources failed to identify a core outcome set (COS) for 
children with appendicitis. We aim to define a COS for the 
measurement of treatment interventions in children (<18 
years) with acute appendicitis.
Methods and analysis This project will entail: (1) a 
systematic review to identify previously reported acute 
uncomplicated appendicitis treatment outcomes; (2) 
assembly of stakeholder panels (paediatric and adult 
surgeons, patients and parents); (3) a three-stage Delphi 
process; and (4) a final consensus meeting to complete 
the COS.
Ethics and registration COS development is part of 
CONservative TReatment of Appendicitis in Children - a 
randomised controlled Trial (Feasibility) (CONTRACT) study, 
for which full ethical approval for CONTRACT has been 
granted. The COS development study is registered with the 
COMET Initiative in May 2017 (http://www. comet- initiative. 
org/ studies/ details/ 987).
bAckground
A lack of knowledge and understanding 
regarding which outcomes are important 
to patients and clinicians may result in 
important outcomes being omitted from 
clinical trials. Differences in outcome selec-
tion and reporting between studies and how 
outcomes are defined and measured also 
make it difficult, sometimes impossible, to 
synthesise results of studies (eg, meta-anal-
ysis) and apply them in a meaningful way. 
To address these problems, core outcome 
sets (COS) have been proposed as a means 
of standardising outcome selection, measure-
ment and reporting in healthcare research 
and in clinical trials in particular.1 2 The 
development of a COS and its adoption by 
researchers is intended to help avoid incon-
sistencies in outcome selection, measurement 
and reporting that may otherwise exist. If 
trials do not adopt an established COS, they 
risk selecting suboptimal outcomes and are 
unlikely to contribute usable information.3
What this study hopes to add?
 ► This project will involve defining a core outcome set 
for the measurement of effectiveness of treatment 
interventions in children with acute uncomplicated 
appendicitis.
 ► Considering outcomes of importance to patients, 
parents of patients and health professionals is 
crucial for paediatric appendicitis research to be 
meaningful and relevant.
Open Access 
Development of a core outcome set to 
determine the overall treatment success 
of acute uncomplicated appendicitis in 
children: a study protocol
Frances C Sherratt,1 Simon Eaton,2 Erin Walker,3 Lucy Beasant,4 Jane M Blazeby,5 
Bridget Young,1 Esther Crawley,4 Wendy W Wood,6 Nigel J Hall7 
To cite: Sherratt FC, Eaton S, 
Walker E, et al. Development 
of a core outcome set to 
determine the overall treatment 
success of acute uncomplicated 
appendicitis in children: a study 
protocol. BMJ Paediatrics Open 
2017;1:e000151. doi:10.1136/
bmjpo-2017-000151
 ► Prepublication history and 
additional material is available. 
To view please visit the journal 
(http:// dx. doi. org/ 10.1136/
bmjpo-2017-000151).
Received 1 June 2017
Revised 20 July 2017
Accepted 24 July 2017
For numbered affiliations see 
end of article.
correspondence to
Dr Frances C Sherratt;  sherratt@ 
liverpool. ac. uk
Protocol
What is already known on this topic?
 ► Traditionally, appendicectomy has been the gold 
standard treatment for acute appendicitis in 
children, but there has been increased interest in 
non-operative treatment (with antibiotics).
 ► Core outcome sets are developed and adopted 
to avoid inconsistencies in outcome selection, 
measurement and reporting that may otherwise 
exist.
 ► There is currently no core outcome set for the 
measurement of effectiveness of treatment 
interventions in children with acute uncomplicated 
appendicitis.
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For children with acute uncomplicated appendicitis, 
appendicectomy has traditionally been the gold stan-
dard treatment, but there has been growing interest in 
alternatives to appendicectomy. In particular, non-op-
erative treatment of appendicitis, with antibiotics, has 
been proposed as a potential treatment. A small number 
of randomised controlled trials (RCTs) in adults4–6 and, 
more recently, RCTs and prospective preference studies 
in children7 8 suggest that antibiotic treatment may be 
a valid alternative to appendicectomy.9 However, there 
is currently insufficient data to justify its widespread 
use. Prior to performing further efficacy studies of the 
treatment of appendicitis in children, it is imperative 
to identify the most relevant outcomes for inclusion in 
the design of comparative studies. This is of particular 
importance when evaluating a novel treatment approach 
since the outcomes of importance may differ from 
those commonly reported with traditional therapies. A 
review of the relevant literature and electronic resources 
failed to identify a COS for children with appendicitis.10 
Furthermore, a wide range of outcomes were reported, 
and a range of different primary outcomes were used 
across studies.
In order to advance our understanding of which 
outcomes are important and to fulfil an unmet need in 
our future research programme, the aim of this study is 
to develop a COS for the measurement of effectiveness 
of treatment interventions in children (<18 years) with 
acute uncomplicated appendicitis.
MEthods
The COS development is a component of a wider project, 
CONservative TReatment of Appendicitis in Children - a 
randomised controlled Trial (Feasibility) (CONTRACT) 
study (http://www. nets. nihr. ac. uk/ projects/ hta/ 
1419290). The COS development study was registered 
with the COMET Initiative in May 2017 (http://www. 
comet- initiative. org/ studies/ details/ 987).
scope of the cos
The COS is intended to be used to evaluate the overall 
success of operative and non-operative treatment among 
children who are assigned a clinical and/or radiological 
diagnosis of acute uncomplicated appendicitis. The COS 
will include outcome measures identified as important 
within 12 months of treatment initiation and longer term 
outcomes if applicable. The COS focuses specifically on 
treatment of acute uncomplicated appendicitis; the treat-
ment of perforated appendicitis (with or without abscess) 
and appendix mass is outside the scope of this COS. The 
key objectives of the study are:
1. to determine which outcomes have previously been 
reported in studies comparing treatments for acute 
uncomplicated appendicitis in children
2. to prioritise treatment outcomes of children with 
acute uncomplicated appendicitis from key stake-
holder groups’ perspectives (including paediatric sur-
geons, general surgeons, patients (12–18 years old) 
and parents of children who have had acute uncom-
plicated appendicitis)
3. to compare and contrast paediatric acute uncompli-
cated appendicitis treatment outcomes prioritised by 
key stakeholder groups (as detailed above)
4. to achieve consensus between key stakeholder groups 
on a COS to evaluate overall success of treatment for 
acute uncomplicated appendicitis in children.
design
COS development will entail four key stages:
1. a systematic review to identify previously reported 
acute uncomplicated appendicitis treatment out-
comes
2. assembly of stakeholder panels
3. a three-phase online Delphi process
4. consensus meeting.
The CONTRACT study, as part of the feasibility study, 
will involve in-depth qualitative research. Interviews will 
be conducted with patients, parents and caregivers to 
explore experiences of treatment for appendicitis. We 
will explore families’ perceptions of meaningful and 
important outcomes, which will help to optimise COS 
participants’ project understanding and engagement 
throughout the COS development.
systematic review
The COMET Initiative recommend the use of systematic 
reviews in informing the first phase of the Delphi process.11 
Two recent systematic reviews will be used to inform the 
initial list of potential outcomes to be considered for the 
COS. The first review identified outcomes used in studies 
of paediatric appendicitis,10 and the second review aimed 
to determine safety and efficacy of non-operative treat-
ment for acute appendicitis.9 Identified outcomes were 
combined with closely similar outcomes from the opera-
tive treatment systematic review10 to develop an initial list 
of outcomes (online supplementary appendix 1). Online 
supplementary appendix 1 describes the eligibility 
criteria for inclusion of papers. All relevant articles will 
therefore be included that reported any non-operative 
treatment regimen for acute uncomplicated appendi-
citis in children with or without a comparative group of 
children undergoing surgical treatment. All outcomes 
identified through these reviews and an updated litera-
ture search will inform the initial list of outcomes and 
will be considered by the stakeholder groups as part of 
the Delphi process.
Finalising and appropriate wording of initial outcomes
To inform and support the CONTRACT study, a Study 
Specific Advisory Group (SSAG) has been assembled, 
comprising 15–20 young people and parents. Young 
people recruited are children who have had appendicitis 
or children from the existing Clinical Research Network 
(Children) Young Persons Advisory Groups. Parents are 
parents of children who have had appendicitis. An SSAG 
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Table 1 Core outcome set stakeholder groups and methods of approaching potential participants
Stakeholder 
group Selection criteria Method of approach
Patients and 
parents
 ► Patients aged 12–18 years who have been treated for acute 
uncomplicated appendicitis in the preceding 12–24 months.
 ► Parents of children (aged 5–18 years) who have been treated for acute 
uncomplicated appendicitis in the preceding 12–24 months.
 ► Families may or may not have participated in CONTRACT.
 ► Patient and parent panels will specifically include children and parents 
treated initially by non-operative management as well as those treated 
operatively.
 ► Invited to participate via clinical 
teams from the three sites 
that are participating in the 
CONTRACT study.
 ► Identified to participate via 




 ► All practising consultant paediatric surgeons in the UK who treat 
children with acute uncomplicated appendicitis will be considered 
potential participants.
 ► Invited to participate via 
the mailing list of the British 
Association of Paediatric 
Surgeons and through personal 
contacts of the investigators.
General 
surgeons
 ► Adult general surgeons in the UK who regularly treat children with acute 
uncomplicated appendicitis will be considered potential participants. 
This will include those identified as having an interest in the treatment of 
children.
 ► Invited to participate via 
existing personal contacts and 
through regional paediatric 
surgical networks within the 
UK.
CONTRACT, CONservative TReatment of Appendicitis in Children—a randomised controlled Trial (Feasibility).
meeting will be held to present the initial list of treat-
ment outcomes, to inform the addition and wording 
of outcomes and to ensure outcomes are appropriately 
presented. Three versions of the stakeholder-facing 
materials will be developed for all rounds of the Delphi 
process, for each stakeholder panel (clinicians, young 
people and parents), using appropriate language identi-
fied and agreed by the SSAG. The CONTRACT qualitative 
study will also inform the initial outcomes.
stakeholder panel assembly: identification and recruitment
For the COS to be meaningful and relevant to those 
involved in the treatment of acute appendicitis, the COS 
needs to reflect the views of patients who have been 
treated for acute appendicitis, their parents and relevant 
clinicians. As these groups may have different priorities 
that could obstruct reaching consensus on a COS, the 
stakeholders will be separated into three panels, which we 
intend to be equally weighted: (1) patients; (2) parents; 
and (3) paediatric surgeons and general surgeons. 
Initially, potential members of each stakeholder panel 
known to the research team will be invited to participate, 
and we will develop strategies to identify further experts 
(see table 1).
Initial contact with potential participants will explain 
the study and why they have been identified as a potential 
participants. It will contain a plain language summary of 
the study aims and procedures, emphasising the impor-
tance of commitment to the panel. The wording of this 
initial contact will be tailored to meet the panel category. 
It will also contain a link to an online form to enable 
participants to express their interest in participation in 
the study and to provide further information on their 
experience of the treatment of acute appendicitis. We will 
ask participants to commit to completing three rounds of 
questionnaires anticipated to take approximately 10 min 
each to complete.
The process of invitation and enrolment will continue 
until the optimal number of stakeholders have expressed 
an interest to participate (with at least 10 in each panel). 
There is no consensus on the optimal sample size for 
a Delphi study; recruitment will therefore be based on 
previous Delphi studies.12 We will aim to achieve 75–100 
participants in the first round of the Delphi with at least 
as many parents/children as clinicians. Efforts will be 
made to invite a diverse range of participants to each 
stakeholder group. We will aim to send the first ques-
tionnaire to all participants on the same day they each 
confirm their desire to participate.13 Participants will be 
sent a link to a customised online database hosted on a 
secure server, from which they can access and complete 
phase one questionnaire of the Delphi process. To limit 
attrition, appropriate procedures will be completed,12 14 
including reminder emails.
Participation in this COS development process will 
be limited to surgeons, patients and parents from the 
UK. We will not recruit paediatric or general surgeons 
from outside the UK because the treatment pathway 
for appendicitis in the UK differs to that in other coun-
tries. Furthermore, if we were to recruit surgeons from 
outside the UK, we would also need to recruit patients 
and parents from outside the UK to avoid bias; this would 
become increasingly challenging logistically.
definition of consensus
During the process, participants will be asked to score 
each outcome using the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) 
group.bmj.com on August 11, 2017 - Published by http://bmjpaedsopen.bmj.com/Downloaded from 
4 Sherratt FC, et al. BMJ Paediatrics Open 2017;1:e000151. doi:10.1136/bmjpo-2017-000151
Open Access
scale, which is recommended by the COMET Initiative.15 
The scale will be presented in the format 1–9, with 1–3 
labelled ‘not important’, 4–6 labelled ‘important but 
not critical’ and 7–9 labelled ‘critical’.16 ‘Consensus 
in’ will be defined as ≥70% of participants rating the 
outcome 7–9 and <15% rating it as 1–3. Outcomes will 
defined as ‘consensus out’ if >70% participants rate it 1–3 
and <15% rate it 7–9. Outcomes not meeting these defini-
tions will be classified as ‘no consensus’.
delphi process: phase one data collection
A customised online data system (developed by the 
National Perinatal Epidemiology Unit (University of 
Oxford, UK)) will be used to conduct a three-phase 
Delphi process run in parallel across the stakeholder 
panels. Participants will be presented with the initial list 
of outcomes, grouped by domains. As described, the 
initial list will comprise outcomes identified in our recent 
systematic review,10 updated review of the literature 
(online supplementary appendix 1) and any additional 
outcomes identified during qualitative interviews with 
key stakeholders. There will also be an option for experts 
to add further outcomes, but these outcomes will not be 
scored in phase one.
Surgeon participants will be asked the key question 
‘How important do you consider the following outcomes 
to be when considering which treatment to offer chil-
dren with uncomplicated acute appendicitis?’ A similar 
question will be posed to patient and parent stakeholder 
panels, with the wording altered as necessary based on 
our SSAG input.
Participants will be asked to complete each round of 
the Delphi exercise within 3 weeks, and two subsequent 
reminder emails will be sent. Participants who have not 
completed the questionnaire within 4 weeks of being 
requested to complete the questionnaire will be deemed 
not to have completed that phase.
delphi process: phase one data analysis
The number of participants who were invited to partic-
ipate in phase one and the response rate from each 
stakeholder group will be recorded. Outcomes will 
be analysed separately for each panel, and descriptive 
statistics will be calculated. All outcomes will be carried 
forward to phase two.
Additional outcomes provided by participants will be 
reviewed by two members of the COS team to ensure they 
represent new outcomes and will be included in phase 
two if they were proposed by at least two participants.
delphi process: phase two data collection
Participants who completed phase one will be invited to 
participate in phase two. Participants will be individually 
presented with their own scores, the distribution of scores 
for each outcome from their stakeholder group in phase 
one, and will be asked to rescore each outcome. Partici-
pants will be asked to score any new outcomes identified 
in phase one.
delphi process: phase two data analysis
The data analysis process described for phase one will 
be repeated. Bias from loss of experts between phases 
will be assessed. Any outcomes that meet the criteria of 
‘consensus out’ will be removed from the outcomes list 
prior to phase three. All other outcomes from phase two 
will be carried forward to phase three.
delphi process: phase three data collection
Participants who completed phases one and two will be 
invited to participate in phase three. The data collec-
tion process described for phase two will be repeated; 
however, participants will also be shown scores for their 
own stakeholder panel and separately for each other 
panel. This will allow participants to consider other stake-
holder groups’ views before rescoring the outcomes.17 
Participants will be asked to identify the one outcome 
which they believe is the most important for informing 
their treatment choice, and if they cannot identify a 
single outcome, a combination of essential outcomes.
delphi process: phase three data analysis
The data analysis process described for phase two will be 
repeated. All outcomes from phase three will be carried 
forward to the consensus meeting.
Final consensus meeting
The aim of the consensus meeting is to ratify outcomes 
where consensus (‘in’ or ‘out’) has been achieved, 
to discuss outcomes where consensus could not be 
achieved and to finalise the COS. All participants who 
have completed all three rounds of the Delphi exer-
cise will be invited to attend the consensus meeting. We 
will aim to have a minimum of 40 stakeholders confirm 
their attendance with equally weighted panels and disci-
plines. Representatives from each stakeholder panel will 
be required in order for the consensus meeting to be 
quorate.
During the meeting, stakeholders will be provided with 
an overview of the results of phase three including presen-
tation of each outcome scored, how it was scored by each 
stakeholder panel and its consensus status. Following 
moderated discussion, each outcome will be anonymously 
rescored using the same scoring system as the Delphi 
process. For outcomes for which ‘no consensus’ was 
achieved across all stakeholder panels at the end of the 
Delphi exercise, and for which consensus was achieved 
in at least one but not all stakeholder groups, further 
discussion will take place, following which attendees will 
be asked to score each outcome anonymously. Following 
rescoring at the consensus meeting, outcomes reaching 
‘consensus in’ will be included in the finalised COS. All 
others will be excluded.
Finalising the cos
The Outcome Measures in Rheumatology initiative 
provides a COS development framework that is a useful 
across various healthcare domains.18 In developing the 
current COS, we will draw on this framework, which 
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comprises three core domains (death, life impact and 
pathophysiological manifestations) and one strongly 
recommended domain (resource use). The frame-
work recommends inclusion of at least one applicable 
measurement instrument for each core domain. It also 
recommends inclusion of ‘adverse events’. Overall, we 
aim to achieve a manageable COS with a maximum of 
approximately 10 outcomes. Beyond the current project, 
further work may be undertaken to establish optimal 
methods of measuring each core outcome18 and subse-
quent work may be undertaken to determine whether 
the UK-based COS is valid internationally.
data management
Experts will enter data directly into the customised data-
base when they complete each questionnaire at each 
phase of the Delphi process. Anonymised data will be 
stored securely and will be managed as per standard 
operating procedures. Only selected members of the 
research team will have access to the data.
Ethics and dissemination
Full ethical approval for CONTRACT was granted by 
South Central - Hampshire A Research Ethics Committee 
(REC ref: 16/SC/0596) in November 2016. The finalised 
COS will be disseminated via publication, events and the 
COMET Initiative website (http://www. comet- initiative. 
org/).
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